2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-118948
    MSN-50 1592908-75-2 98.68%
    MSN-50 is a Bax and Bak oligomerization inhibitor. MSN-50 efficiently inhibits liposome permeabilization, prevents genotoxic cell death and promotes neuroprotection.
    MSN-50
  • HY-128205
    BTD 896684-04-1 99.78%
    BTD is a selective transient receptor potential canonical 5 (TRPC5) activator. BTD can be used for the research of neurological disease.
    BTD
  • HY-134542
    CaV1.3 antagonist-1 1391385-57-1 98.38%
    CaV1.3 antagonist-1 is a potent and highly selective CaV1.3 L-type calcium channel (LTCC) antagonist with an IC50 of 1.7 μM. CaV1.3 antagonist-1 inhibits CaV1.3 LTCC >600-fold more potently than CaV1.2 LTCC. CaV1.3 antagonist-1, a cyclopentyl derivative, has the potential for Parkinson's disease research.
    CaV1.3 antagonist-1
  • HY-145468
    GPR52 antagonist-1 1239987-91-7 99.80%
    GPR52 antagonist-1 (Compound 43) is a GPR52 antagonist with an IC50 of 0.63 μM. GPR52 antagonist-1 reduces mHTT (mutant huntingtin protein) levels by targeting GPR52 and promotes survival of mouse primary striatal neurons.
    GPR52 antagonist-1
  • HY-156650
    Votoplam 2407849-89-0 99.51%
    Votoplam (PTC518) (Example 37) is an HTT gene regulator with an IC50 ≤ 0.1 μM. Votoplam can be used in the research of Huntington's disease.
    Votoplam
  • HY-16361A
    Omigapil maleate 200189-97-5 99.84%
    Omigapil maleate, an orally bioavailable GAPDH nitrosylation inhibitor, abrogates Aβ1-42-induced tau acetylation, memory impairment, and locomotor dysfunction in mice. Omigapil maleate has the potential for the research of Alzheimer's disease. Omigapil maleate (CGP3446B maleate) is a apoptosis inhibitor. Omigapil maleate can be used for the research of congenital muscular dystrophy (CMD). Omigapil (maleate) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    Omigapil maleate
  • HY-D0187S
    L-Glutathione reduced-13C2,15N 815610-65-2 ≥99.0%
    L-Glutathione reduced-13C2,15N is the 13C- and 15N-labeled L-Glutathione reduced. L-Glutathione reduced (GSH) is an endogenous antioxidant and is capable of scavenging oxygen-derived free radicals.
    L-Glutathione reduced-13C2,15N
  • HY-P0242A
    Neurokinin B TFA 101536-55-4 98.59%
    Neurokinin B TFA belongs to the tachykinin family of peptides. Neurokinin B binds a family of GPCRs-including neurokinin receptor 1 (NK1R), NK2R, and NK3R-to mediate their biological effect.
    Neurokinin B TFA
  • HY-P1221A
    ProTx II TFA 99.72%
    ProTx II TFA is a selective blocker of Nav1.7 sodium channels with an IC50 of 0.3 nM, and is at least 100-fold selective for Nav1.7 over other sodium channel subtypes. ProTx-II inhibits sodium channels by decreasing channel conductance and shifting activation to more positive potentials and blocks action potential propagation in nociceptors.
    ProTx II TFA
  • HY-P1467A
    [Met5]-Enkephalin, amide TFA 2918768-28-0 99.58%
    [Met5]-Enkephalin, amide TFA is an agonist for δ opioid receptors as well as putative ζ (zeta) opioid receptors.
    [Met5]-Enkephalin, amide TFA
  • HY-100806R
    Kynurenic acid (Standard) 492-27-3
    Kynurenic acid (Standard) is the analytical standard of Kynurenic acid. This product is intended for research and analytical applications. Kynurenic acid, an endogenous tryptophan metabolite, is a broad-spectrum antagonist targeting NMDA, glutamate, α7 nicotinic acetylcholine receptor. Kynurenic acid is also an agonist of GPR35/CXCR8.
    Kynurenic acid (Standard)
  • HY-107523A
    WAY-213613 hydrochloride 2450268-84-3 99.78%
    WAY-213613 (hydrochloride) is a potent and selective human EAAT2 inhibitor. WAY-213613 has potent EAAT2 inhibitory activity with an IC50 value of 85 nM. WAY-213613 can be used for the research of central nervous system.
    WAY-213613 hydrochloride
  • HY-134398A
    Kinetin triphosphate tetrasodium
    Kinetin triphosphate(6-Fu-ATP) tetrasodium is an ATP analogue that regulates or enhances kinase function with higher catalytic efficiency than its endogenous substrate, ATP. Kinetin triphosphate tetrasodium can be used in Parkinson's disease research.
    Kinetin triphosphate tetrasodium
  • HY-W007686
    Imidazoleacetic acid hydrochloride 3251-69-2 ≥98.0%
    Imidazoleacetic acid hydrochloride is a γ-aminobutyric acid receptor agonist. Imidazoleacetic acid hydrochloride inhibits GABA-T in a non-competitive manner, with a Ki value of 0.34 mM. Imidazoleacetic acid hydrochloride increases total free GABA in brain.
    Imidazoleacetic acid hydrochloride
  • HY-W011956
    6-Hydroxymelatonin 2208-41-5 ≥98.0%
    6-Hydroxymelatonin is a primary metabolic of Melatonin, which is metabolized by cytochrome P450 (CYP) 1A2.
    6-Hydroxymelatonin
  • HY-W014589
    2,4-Di-tert-butylphenol 96-76-4 99.97%
    2,4-Di-tert-butylphenol (2,4-DTBP) is an orally active RXRα activator and a human estrogen receptor ligand with anti-inflammatory and antioxidant activities, which can induce apoptosis in tumor cells. 2,4-Di-tert-butylphenol can activate the RXRα subtype in LXRα/RXRα, PPARγ/RXRα, and hormone receptor β/RXRα. 2,4-Di-tert-butylphenol also has antiviral and antifungal activities and has the potential to inhibit Aβ-induced neurotoxicity. 2,4-Di-tert-butylphenol can be used as an intermediate in the preparation of antioxidants and UV stabilizers, and is also used in the manufacture of drugs and fragrances.
    2,4-Di-tert-butylphenol
  • HY-Y0966S3
    Glycine-13C2 67836-01-5 99.10%
    Glycine-13C2 is the 13C-labeled Glycine. Glycine is an inhibitory neurotransmitter in the CNS and also acts as a co-agonist along with glutamate, facilitating an excitatory potential at the glutaminergic N-methyl-D-aspartic acid (NMDA) receptors.
    Glycine-13C2
  • HY-W013636R
    2-Ketoglutaric acid (Standard) 328-50-7 99.52%
    2-Ketoglutaric acid (Standard) (Alpha-Ketoglutaric acid (Standard)) is the analytical standard of 2-Ketoglutaric acid (HY-W013636). This product is intended for research and analytical applications. 2-Ketoglutaric acid (Alpha-Ketoglutaric acid) is an intermediate in the production of ATP or GTP in the Krebs cycle. 2-Ketoglutaric acid also acts as the major carbon skeleton for nitrogen-assimilatory reactions. 2-Ketoglutaric acid is a reversible inhibitor of tyrosinase (IC50=15 mM).
    2-Ketoglutaric acid (Standard)
  • HY-17455
    Pramiracetam 68497-62-1 ≥98.0%
    Pramiracetam (CI-879 free base) is a PREP (prolyl endopeptidase) inhibitor. Pramiracetam improves cognitive impairment caused by traumatic brain injury. Pramiracetam can be used in the study of neurodegenerative diseases.
    Pramiracetam
  • HY-108964
    Carvone 99-49-0
    Carvone is a ketone monoterpene found mostly in the essential oils from plants of the genus Mentha. Carvone is widely used in the pharmaceutical industry, cosmetics and agriculture. Carvone has such effects as antimicrobial, antioxidant, anti-inflammatory, antispasmodic, antinociceptive, anticonvulsant.
    Carvone
Cat. No. Product Name / Synonyms Application Reactivity